Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, Diffused-type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor.本發明揭示一種衍生自序列識別號：50及其片段之單離胜肽，其連接於HLA抗原並誘導細胞毒性T淋巴球(CTL)，因此適用於癌症免疫療法，更可稱為癌症疫苗。本發明的胜肽包括上述胺基酸序列及其修飾者，其中有1、2個或以上的胺基酸序列經取代、刪除、增加或插入，惟此述修飾者保留原始序列的必要的細胞毒性T細胞誘導能力。本發明更提供編碼上述任一胜肽的核酸，及包括或含有上述任一胜肽或核酸的醫藥製劑、物質及/或組合物。本發明之胜肽、核酸、醫藥製劑、物質及組合物，特別有用於癌症及腫瘤的治療，包括例如AML、膀胱癌、乳癌、子宮頸癌、膽管細胞癌、CML、大腸直腸癌、食道癌、擴散型胃癌、肝癌、NSCLC、淋巴癌、骨肉瘤、卵巢癌、胰臟癌、前列腺癌、腎癌、SCLC、軟組織腫瘤及睪丸腫瘤。
